New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor; Change of Sponsor Address
Published Date: 2/6/2026
Rule
Summary
The FDA updated rules for new animal drugs approved between July and September 2025, including approvals, withdrawals, and sponsor changes. These updates affect drug makers, vets, and farmers by keeping drug info accurate and easy to find. The changes take effect February 6, 2026, helping everyone stay on the same page without extra costs.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
New drug use and withdrawal limits
The rule adds specific conditions of use for certain drugs. For doramectin in cattle, you may not slaughter treated cattle for human consumption within 35 days of treatment, it is not for use in female dairy cattle 20 months of age or older, no withdrawal period is established for preruminating calves, and do not use in calves to be processed for veal. For fluralaner oral solution in chickens, treated chickens must not be slaughtered for human consumption for 11 days after the last treatment, and no egg discard is required when used according to labeling.
Animal drug rules updated (July–Sept 2025)
The FDA amended animal drug regulations to reflect approvals, withdrawals, and sponsor changes for new animal drug applications during July, August, and September 2025. The rule is effective February 6, 2026. FDA says these updates affect drug makers, veterinarians, and farmers by keeping drug information accurate and easy to find and that the changes take effect without extra costs.
Fluralaner food-residue limits set
FDA established an acceptable daily intake (ADI) for total fluralaner residue of 10 micrograms per kilogram of body weight per day and tolerances for parent fluralaner in chickens: liver 320 ppb, muscle 110 ppb, and eggs 2500 ppb. These tolerances are tied to the fluralaner chicken use described in Sec. 520.999.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06379 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KRESLADI (marnetegragene autotemcel)
The FDA just gave Rocket Pharmaceuticals a special priority review voucher for their rare pediatric disease treatment, KRESLADI, approved on March 26, 2026. This voucher speeds up future FDA reviews, helping get important medicines to kids with rare diseases faster. It’s a big win for patients, the company, and anyone cheering for quicker cures!
2026-06314 — Determination That INAPSINE (Droperidol) Injection, 2.5 Milligrams/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that INAPSINE (droperidol) injection wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can keep being approved and sold as long as they follow the rules. Patients and healthcare providers can keep trusting this medicine without worry, and drug makers can continue their work without delays or extra costs.
2026-06294 — Consideration of Acceptable Market Name Change for Certain Rockfish (Sebastes spp.); Request for Information
The FDA wants to hear from fishermen, seafood sellers, and fish lovers about possibly changing the official market names for certain rockfish species. This update aims to make fish labels clearer and safer for everyone, with comments open until May 1, 2026. If the name changes happen, it could affect how these fish are sold and marketed, so your input matters!
2026-06316 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; YUVIWEL (navepegritide)
The FDA just gave Ascendis Pharma a special priority review voucher for their rare pediatric disease drug, YUVIWEL, which helps kids with achondroplasia grow taller. This voucher speeds up future drug reviews and can be a valuable asset, saving time and potentially money. Approved on February 27, 2026, this move highlights the FDA’s commitment to fast-tracking treatments for rare childhood conditions.
2026-06187 — Notice of Decision on a Hearing Request Regarding a Proposal To Refuse To Approve a New Drug Application for TRADIPITANT Capsules
The FDA has decided not to approve Vanda Pharmaceuticals’ new drug, TRADIPITANT capsules, meant to treat symptoms of gastroparesis. Vanda asked for a hearing to challenge this, but the FDA denied it. This means patients and doctors will have to wait longer for this treatment, and Vanda faces delays and extra costs as they figure out their next move.
2026-05913 — Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction
The FDA fixed a mistake about pulling approvals for 72 generic drug applications. One drug, a valproic acid capsule from Upsher-Smith Laboratories, won’t lose its approval because the company asked to keep it. This means the drug stays available, and the change took effect before October 23, 2025.
Previous / Next Documents
Previous: 2026-02326 — Appellate Procedures for the Board of Immigration Appeals
Starting March 9, 2026, the Board of Immigration Appeals will change how it reviews cases from Immigration Judges. Now, the Board can choose which cases to review fully, set clear deadlines for briefs, and speed up decisions to cut down the backlog. These updates affect immigrants appealing decisions and aim to make the process faster without extra costs.
Next: 2026-02335 — Safety Zone; Chicago Sanitary and Ship Canal, Chicago, IL
From February 7 to 22, 2026, the Coast Guard will block off a 2-mile stretch of the Chicago Sanitary and Ship Canal for electric fish barrier testing. Boats can’t enter or anchor there during certain morning and afternoon hours unless they get special permission. This keeps everyone safe while the testing happens, so plan your trips accordingly!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in